Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02484651
Other study ID # 2014.145
Secondary ID 2014-005238-76
Status Completed
Phase Phase 4
First received
Last updated
Start date September 2016
Est. completion date July 1, 2017

Study information

Verified date September 2019
Source Centro Hospitalar do Porto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hypothesize that an anesthetic protocol maintaining deep neuromuscular block throughout the entire surgical procedure followed by sugammadex reversal, would suppress EMG activity and result in improved anesthetic stability by reducing the variability of the Bispectral Index of the EEG, and be beneficial by reducing the total doses of the anesthetic drugs propofol and remifentanil required to maintain an adequate level of anesthesia (BIS between 40 and 60).


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date July 1, 2017
Est. primary completion date June 28, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients ASA I-III

- Between 18 - 80 years old

- Scheduled for routine cervical surgery

- Minimum duration of surgery is 90 minutes and performed with total intravenous anaesthesia (TIVA) with the hypnotic propofol, the analgesic remifentanil and the neuromuscular relaxant rocuronium

- Patients that are able to and do provide a signed informed consent form

Exclusion Criteria:

- Patients with neuromuscular diseases and severe cardiac and respiratory pathologies

- Contra indication for any of the drugs used

- Not able to complete the baseline PQRS test.

- Indication to perform tracheal intubation using fibroscopy

- Patients who are pregnant or nursing

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sugammadex
Reversal of deep neuromuscular block
Rocuronium
Maintenance of deep neuromuscular block

Locations

Country Name City State
Portugal Centro Hospitalar do Porto Porto

Sponsors (2)

Lead Sponsor Collaborator
Centro Hospitalar do Porto Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary BIS Signal Variability Using the Measured Standard Deviation During the Maintenance Phase of Anesthesia BIS (Bispetral Index of the EEG) sample standard deviation during the maintenance phase of anesthesia was used as a measure of signal variability, maintenance phase is defined as the time between the first time the BIS signal drops below 60 after loss of consciousness, until the time the BIS signal goes above 60 after the propofol infusion is stopped. BIS signal varies between 0 to 100. BIS values near 100 represent an "awake" clinical state while 0 denotes the maximal effect an isoelectric EEG. The aim was to maintain the BIS value within a target range of 40 to 60. The higher the BIS sample standard deviation the higher the oscillation around the sample mean. Maintenance of anesthesia, an average of 130 minutes
Primary Required Effect-site Concentrations of Propofol and Remifentanil Mean effect-site concentration of propofol required during maintenance of anesthesia (using target controlled infusion).
Mean effect-site concentration of remifentanil required during maintenance of anesthesia (using target controlled infusion).
Maintenance of anesthesia, an average of 130 minutes
Secondary PQRS Results at 15 and 40 Minutes After Surgery (Taking Into Account the Patient Baseline Values of the PQRS Test Done on the Preanesthetic Visit) PQRS(Post-operative Quality Recovery Scale) recovery rate at 15 minutes post surgery and PQRS recovery rate at 40 minutes post surgery. Recovery is defined as returning to PQRS baseline values. 15 and 40 minutes after surgery
Secondary PQRS Satisfaction Results at Day 3 After Surgery Patient satisfaction with anesthetic care rated as: Not satisfied, A little satisfied, Moderately satisfied ,Satisfied, Totally Satisfied 3rd day after surgery
See also
  Status Clinical Trial Phase
Completed NCT01440933 - Efficacy of Sugammadex in Magnesium Pretreated Patients Phase 2
Recruiting NCT02778945 - Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery Phase 4
Recruiting NCT02966249 - Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty Phase 4
Completed NCT02838134 - Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery Phase 4
Completed NCT03734250 - D Vitamin Effects on Neuromuscular Blocker Reverse Time
Not yet recruiting NCT03287388 - MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy N/A
Completed NCT01791036 - Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair N/A
Not yet recruiting NCT02648503 - Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy Phase 4
Completed NCT00895609 - Sugammadex and Neostigmine at Shallow Neuromuscular Blockade Phase 4
Completed NCT02483611 - Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block Phase 4
Completed NCT02320734 - Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Phase 4
Recruiting NCT05005676 - Evaluation of the New Acceleromyograph TOF 3D N/A
Not yet recruiting NCT03460509 - Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Phase 4
Completed NCT00828373 - The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium Phase 4